Aller au contenu
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Langue
Tous les champs
Titre
Auteur
Sujet
Cote
ISBN/ISSN
Tag
Rechercher
Recherche avancée
Future of flu vaccines. Expedi...
Citer
Envoyer par SMS
Envoyer par courriel
Imprimer
Exporter les notices
Exporter vers RefWorks
Exporter vers EndNoteWeb
Exporter vers EndNote
Permalien
Future of flu vaccines. Expediting clinical trials in a pandemic.
Afficher d'autres versions (1)
Détails bibliographiques
Auteurs principaux:
Pollard, A
,
Reiner, A
,
John, T
,
Sheasby, E
,
Snape, M
,
Faust, S
,
Collinson, A
,
Finn, A
,
Heath, P
,
Miller, E
Format:
Journal article
Langue:
English
Publié:
2009
Exemplaires
Description
Autres Versions (1)
Documents similaires
Affichage MARC
Documents similaires
Future of flu vaccines. Expediting clinical trials in a pandemic.
par: Pollard, A, et autres
Publié: (2009)
Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
par: Walker, W, et autres
Publié: (2011)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
par: Waddington, C, et autres
Publié: (2010)
Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
par: Waddington, C, et autres
Publié: (2010)
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
par: Waddington, C, et autres
Publié: (2010)